Articles Published in 2014

Cromos Pharma launches risk-sharing partnerships program

Friday, December 19, 2014 02:33 PM

Portland, Ore.-based CRO Cromos Pharma, which operates predominantly in Eastern/Central Europe, has implemented a risk-sharing platform partnering with biotech, pharma and device companies with promising drug, biologics or medical device technologies.

More... »


14 indicted in connection with 2012 nationwide fungal meningitis outbreak

Friday, December 19, 2014 02:29 PM

The Justice Department unsealed a 131-count criminal indictment in Boston in connection with the 2012 nationwide fungal meningitis outbreak. Barry J. Cadden, owner and head pharmacist of New England Compounding Center (NECC), and NECC’s supervisory pharmacist Glenn A. Chin were charged with 25 acts of second-degree murder in Florida, Indiana, Maryland, Michigan, North Carolina, Tennessee and Virginia.   

More... »


Seven more research organizations earn AAHRPP accreditation

Friday, December 19, 2014 01:02 PM

The Association for the Accreditation of Human Research Protection Programs (AAHRPP) has accredited seven more organizations: four in the U.S. and three in Asia, including the first organization in Thailand.

More... »

Roche acquires Bina Technologies, enters genomic informatics market

Friday, December 19, 2014 01:00 PM

Roche has acquired Bina Technologies, a privately held company based in Redwood City, Calif. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data. Bina's proprietary on-market Genomic Management Solution, Bina-GMS, empowers basic, translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data.

More... »

Merck acquires OncoEthix, a privately-held oncology company

Friday, December 19, 2014 12:06 PM

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based, privately held biotechnology company specializing in oncology drug development. Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, currently in phase Ib studies for the treatment of hematological malignancies and advanced solid tumors.

More... »

RXi Pharmaceuticals, Hapten Pharmaceuticals ink agreement

Friday, December 19, 2014 12:05 PM

RXi Pharmaceuticals, a Marlborough, Mass.,-based biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, an early stage dermatology product development company based in New York, for the therapeutic use of Samcyprone.

More... »

Sorrento, Conkwest collaborate for cancer immunotherapies

Friday, December 19, 2014 12:03 PM

Sorrento Therapeutics, an oncology company based in San Diego, Calif., and Conkwest, a Cardiff-by-the-Sea, Calif.-based, privately-held immuno-oncology company developing proprietary Neukoplast (NK-92), a natural killer cell-line based therapy, have entered into a definitive agreement to jointly develop next generation CAR-TNK immunotherapies for the treatment of cancer.

More... »

Lilly, Adocia ink alliance for ultra-rapid insulin based on BioChaperone

Friday, December 19, 2014 12:02 PM

Eli Lilly and Adocia, a France-based clinical-stage biotechnology company, have announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone technology and currently is in phase Ib studies.

More... »

New FDA-sponsored research: National and international device registries needed

Thursday, December 18, 2014 11:23 AM

Most Americans will be exposed to a medical device during their lives and tens of millions will receive an implantable device. However, public health and regulatory agencies in the U.S. and internationally acknowledge there are gaps both in the ability to track these devices and to provide the public the accurate, evidence-based information consumers need to improve their health and make informed care decisions.

More... »

Report: Top 30 pharma companies spent $112B on R&D in 2013

Thursday, December 18, 2014 11:19 AM

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on R&D in 2013, an increase of $723 million over the previous year, according to London-based research and consulting firm GlobalData.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs